Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides

Aeglea BioTherapeutics · 2020-08
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON
Narrative range 4 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
0/2 slides
0/2 slides
0/2 slides
100% 2/2 slides
0/2 slides
Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
0/1 slides
0/1 slides
0/1 slides
100% 1/1 slides
0/1 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
0/1 slides

Slide inventory

28
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a 3-column layout to map programs to their respective 2020 momentum/milestones.show_traction
04
The slide uses a process-oriented chevron diagram to map strategic pillars to specific risk mitigation areas.present_solution
05
The chart uses a Gantt-style visualization to represent clinical and preclinical development stages.plan_implementation
06
Includes regulatory status callout.present_solution
Open slide detailBeat · Solution
07
The slide uses a structured table format to define the disease context.frame_problem
Open slide detailBeat · Problem
08
Includes a visual demonstration of spastic diplegia in a patient.frame_problem
Open slide detailBeat · Problem
09
Includes clinical trial data (101A/102A) and baseline demographics for n=16 patients.analyze_data
10
The chart shows a box plot progression from baseline to week 56, demonstrating efficacy in reaching target ranges.show_traction
11
The slide uses a color-coded heatmap to visualize patient improvement against baseline deficits.show_traction
12
The slide outlines a strategic approach to trial design using four key pillars: Disease Burden, Known Impact, Look A-Like Condition, and Patient Feedback.present_framework
13
The slide uses a process flow diagram to illustrate the clinical trial phases.present_framework
14
The slide uses a geographic map to visualize addressable market segments based on genetic prevalence data.size_opportunity
Open slide detailBeat · Market Size
15
plan_implementation
16
summarize
17
present_solution
18
The slide uses a structured table format to define the clinical problem space.frame_problem
19
The slide uses a structured list format to contrast current care with its inadequacies.frame_problem
20
The slide uses a Kaplan-Meier survival curve and a comparative table to illustrate the severity of the disease.frame_problem
Open slide detailLoop · Cost Of Inaction
21
The chart is a Kaplan-Meier survival curve showing significant improvement over the PBS negative control.present_solution
Open slide detailLoop · Cost Of Inaction
22
The slide outlines a sequential cohort design for a clinical trial, moving from IV to SC administration.plan_implementation
23
present_solution
24
The slide uses a simple table-like structure to define the problem space for a specific drug program.frame_problem
25
Includes medical imagery of kidney stones to illustrate the problem.frame_problem
26
Includes a before/after microscopy image showing crystal clearance.present_solution
27
present_solution
28
front_matter